Loading clinical trials...
Loading clinical trials...
HRDx-Ovarian. A Cross-sectional, Noninterventional, Multicentre Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer.
Conditions
Locations
24
Kuwait
Research Site
Kuwait City, Kuwait
Research Site
Muscat, Oman
Research Site
Doha, Qatar
Research Site
Balashikha, Moscow Oblast, Russia
Research Site
Istra Settlement, Moscow Oblast, Russia
Research Site
Kolomna, Moscow Oblast, Russia
Start Date
May 2, 2021
Primary Completion Date
August 15, 2022
Completion Date
August 15, 2022
Last Updated
February 6, 2024
NCT05281471
NCT04657068
NCT06290193
NCT06855706
NCT04590326
NCT05867251
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions